{"Q": 1, "answer": "no", "rationale": "No intensifier or comparative directly modifies a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17084", "batch_size": 200, "batch_pos": 65, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The language is factual reporting of actions and purpose, lacking high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_18056", "batch_size": 200, "batch_pos": 25, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment describes a plan/action ('are already developing or about to test') and lacks a moderate verb paired with realised impact.", "method": "llm_batch", "batch_id": "batch_3_4624", "batch_size": 200, "batch_pos": 160, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_14824", "batch_size": 200, "batch_pos": 134, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "This reports vaccine development (preparedness) but lacks explicit calming keywords.", "method": "llm_batch", "batch_id": "batch_5_14564", "batch_size": 200, "batch_pos": 130, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "Bare numeral 'three vaccine manufacturers' is not a minimiser.", "method": "llm_batch", "batch_id": "batch_6_15948", "batch_size": 200, "batch_pos": 91, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_18984", "batch_size": 200, "batch_pos": 76, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes ongoing development/testing ('are already developing or about to test sample human vaccines') without explicit calming.", "method": "llm_batch", "batch_id": "batch_8_13088", "batch_size": 200, "batch_pos": 131, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
